Although colorectal cancer (CRC) is the third most frequent cause of cancer related death in Europe, clinically relevant biomarkers for therapy guidance and prognosis are insufficiently reliable. Long non-coding RNAs (lncRNAs) are RNAs over 200 nucleotides long that are not translated into proteins but can influence biological processes. There is emerging evidence for their involvement in solid cancer as oncogenes, tumour suppressors or regulators of cell proliferation and metastasis development. The goal of this study was to evaluate the prognostic effect of selected lncRNAs in a retrospective study on CRC patients from the Czech Republic. We used a quantitative PCR approach to measure the expression in paired non-malignant and tumour tissue samples of CRC patients of nine lncRNAs previously shown to be involved in cancer progression-ANRIL, CCAT1, GAS5, linc-ROR, MALAT1, MIR155HG, PCAT1, SPRY4-IT1 and TUG1. Associations between expression and expression ratios and clinical characteristics and survival were assessed by using univariable Cox proportional hazards models, Kaplan-Meier estimations with the Gehan-Wilcoxon test, the Mann-Whitney U test, the Kruskal-Wallis test and Spearman's correlations. A comparison of expression in tumour tissue (TT) and non-malignant mucosa tissue (MT) showed significant upregulation of CCAT1 and linc-ROR in TT (p < 0.001 and p = 0.001, respectively) and downregulation of ANRIL, MIR155HG and MALAT1 (p = 0.001, p = 0.010, p = 0.001, respectively). Linc-ROR was significantly associated with the presence of synchronous metastases (p = 0.033). For individual tissue types, lower MIR155HG expression in TT was correlated with both shorter overall survival (p = 0.008) and shorter disease-free survival (p = 0.040). In MT, expression ratios of CCAT1/ANRIL and CCAT1/MIR155HG were associated with overall survival (p = 0.005 and p = 0.006, respectively). Our results revealed that changes in expression of lncRNAs between MT and TT hold potential to be used as prognostic biomarkers in CRC patients. Moreover, the ratios of CCAT1 to ANRIL and MIR155HG in MT also exhibit potential for prognosis assessment without tumour sampling. Our results also indicate that cancer progression is associated with detrimental system-wide changes in patient tissue, which might govern patient survival even after successful elimination of tumour or cancerous cells.

Biomedical Centre Faculty of Medicine in Pilsen Charles University Alej Svobody 76 32300 Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Karlovarska 48 30166 Pilsen Czech Republic

Department of Molecular Biology of Cancer Institute of Experimental Medicine of the Czech Academy of Sciences Videnska 1083 14220 Prague Czech Republic

Department of Surgery Faculty of Medicine in Pilsen Charles University Alej Svobody 80 32300 Pilsen Czech Republic

Institute of Biology and Medical Genetics 1st Faculty of Medicine Albertov 4 Charles University 12800 Prague Czech Republic

Zobrazit více v PubMed

Malvezzi M., Carioli G., Bertuccio P., Boffetta P., Levi F., Vecchia C.L., Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann. Oncol. 2017;28:1117–1123. doi: 10.1093/annonc/mdx033. PubMed DOI

Siegel R.L., Miller K.D., Fedewa S.A., Ahnen D.J., Meester R.G.S., Barzi A., Jemal A. Colorectal cancer statistics, 2017. CA. Cancer J. Clin. 2017;67:177–193. doi: 10.3322/caac.21395. PubMed DOI

What Are the Survival Rates for Colorectal Cancer, By Stage? [(accessed on 2 February 2018)]; Available online: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html.

Can Colorectal Polyps and Cancer Be Found Early? [(accessed on 2 February 2018)]; Available online: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html.

Hu X., Sood A.K., Dang C.V., Zhang L. The role of long noncoding RNAs in cancer: The dark matter matters. Curr. Opin. Genet. Dev. 2018;48:8–15. doi: 10.1016/j.gde.2017.10.004. PubMed DOI PMC

Svoboda M., Slyskova J., Schneiderova M., Makovicky P., Bielik L., Levy M., Lipska L., Hemmelova B., Kala Z., Protivankova M., et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35:1510–1515. doi: 10.1093/carcin/bgu055. PubMed DOI

Zhang J., Zhang P., Wang L., Piao H.L., Ma L. Long non-coding RNA HOTAIR in carcinogenesis and metastasis. Acta Biochim. Biophys. Sin. 2014;46:1–5. doi: 10.1093/abbs/gmt117. PubMed DOI PMC

Qiao L., Liu X., Tang Y., Zhao Z., Zhang J., Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci. 2017;188:37–44. doi: 10.1016/j.lfs.2017.08.024. PubMed DOI

Shen X., Bai Y., Luo B., Zhou X. Upregulation of lncRNA BANCR associated with the lymph node metastasis and poor prognosis in colorectal cancer. Biol. Res. 2017;50:32. doi: 10.1186/s40659-017-0136-5. PubMed DOI PMC

Yin D., He X., Zhang E., Kong R., De W., Zhang Z. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med. Oncol. 2014;31:253. doi: 10.1007/s12032-014-0253-8. PubMed DOI

Wang L., Zhao Z., Feng W., Ye Z., Dai W., Zhang C., Peng J., Wu K. Long non-coding RNA TUG1 promotes colorectal cancer metastasis via EMT pathway. Oncotarget. 2016;7:51713–51719. doi: 10.18632/oncotarget.10563. PubMed DOI PMC

Jin J., Chu Z., Ma P., Meng Y., Yang Y. Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion by acting as a ceRNA of miR-101-3p in colorectal cancer cells. Tumor Biol. 2017;39 doi: 10.1177/1010428317716250. PubMed DOI

Zhou P., Sun L., Liu D., Liu C., Sun L. Long non-coding rna lincrna-ror promotes the progression of colon cancer and holds prognostic value by associating with miR-145. Pathol. Oncol. Res. 2016;22:733–740. doi: 10.1007/s12253-016-0061-x. PubMed DOI

Lu X., Liu Z., Ning X., Huang L., Jiang B. The long noncoding RNA HOTAIR promotes colorectal cancer progression by sponging miR-197. Oncol. Res. 2017 doi: 10.3727/096504017X15105708598531. PubMed DOI PMC

Zheng H.T., Shi D.B., Wang Y.W., Li X.X., Xu Y., Tripathi P., Gu W.L., Cai G.X., Cai S.J. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int. J. Clin. Exp. Pathol. 2014;7:3174–3181. PubMed PMC

He X., Tan X., Wang X., Jin H., Liu L., Ma L., Yu H., Fan Z. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumor Biol. 2014;35:12181–12188. doi: 10.1007/s13277-014-2526-4. PubMed DOI

Sun Y., Zheng Z.P., Li H., Zhang H.Q., Ma F.Q. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. Mol. Med. Rep. 2016;14:1714–1720. doi: 10.3892/mmr.2016.5409. PubMed DOI

Zhang A., Zhou N., Huang J., Liu Q., Fukuda K., Ma D., Lu Z., Bai C., Watabe K., Mo Y.Y. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23:340–350. doi: 10.1038/cr.2012.164. PubMed DOI PMC

Wu X., Wang Y., Yu T., Nie E., Hu Q., Wu W., Zhi T., Jiang K., Wang X., Lu X., et al. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017;19:1195–1205. doi: 10.1093/neuonc/nox017. PubMed DOI PMC

Li Q., Dai Y., Wang F., Hou S. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma. 2016;63:977–983. doi: 10.4149/neo_2016_617. PubMed DOI

Zhong L., Liu J., Hu Y., Wang W., Xu F., Xu W., Han J., Biskup E. STK31 as novel biomarker of metastatic potential and tumorigenicity of colorectal cancer. Oncotarget. 2017;8:24354–24361. doi: 10.18632/oncotarget.15396. PubMed DOI PMC

Jones C.D., Darnell K.H., Warnke R.A., Zehnder J.L. CyclinD1/CyclinD3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma. J. Mol. Diagn. 2004;6:84–89. doi: 10.1016/S1525-1578(10)60494-1. PubMed DOI PMC

Eis P.S., Tam W., Sun L., Chadburn A., Li Z., Gomez M.F., Lund E., Dahlberg J.E. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA. 2005;102:3627–3632. doi: 10.1073/pnas.0500613102. PubMed DOI PMC

Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA. 2010;107:6982–6987. doi: 10.1073/pnas.1002472107. PubMed DOI PMC

Teng G., Papavasiliou F.N. Shhh! Silencing by microRNA-155. Philos. Trans. R. Soc. B Biol. Sci. 2009;364:631–637. doi: 10.1098/rstb.2008.0209. PubMed DOI PMC

Zhang G.J., Xiao H.X., Tian H.P., Liu Z.L., Xia S.S., Zhou T. Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int. J. Mol. Med. 2013;31:1375–1380. doi: 10.3892/ijmm.2013.1348. PubMed DOI

Liu J., Chen Z., Xiang J., Gu X. MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro. Oncol. Lett. 2018;15:5561–5568. doi: 10.3892/ol.2018.8069. PubMed DOI PMC

Kim S., Song J.H., Kim S., Qu P., Martin B.K., Sehareen W.S., Haines D.C., Lin P.C., Sharan S.K., Chang S. Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration. Oncotarget. 2016;7:11094–11112. doi: 10.18632/oncotarget.7150. PubMed DOI PMC

Chen S., Zhang J.Q., Chen J.Z., Chen H.X., Qiu F.N., Yan M.L., Chen Y.L., Peng C.H., Tian Y.F., Wang Y.D. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: An in vivo and in vitro study. Int. J. Biol. Macromol. 2017;102:718–728. doi: 10.1016/j.ijbiomac.2017.03.123. PubMed DOI

Sun Z., Ou C., Ren W., Xie X., Li X., Li G. Downregulation of long non-coding RNA ANRIL suppresses lymphangiogenesis and lymphatic metastasis in colorectal cancer. Oncotarget. 2016;7:47536–47555. doi: 10.18632/oncotarget.9868. PubMed DOI PMC

Congrains A., Kamide K., Ohishi M., Rakugi H. ANRIL: Molecular Mechanisms and Implications in Human Health. Int. J. Mol. Sci. 2013;14:1278–1292. doi: 10.3390/ijms14011278. PubMed DOI PMC

Cunnington M.S., Santibanez Koref M., Mayosi B.M., Burn J., Keavney B. Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS Genet. 2010;6:e1000899. doi: 10.1371/journal.pgen.1000899. PubMed DOI PMC

Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137:647–658. doi: 10.1016/j.cell.2009.02.038. PubMed DOI

Ge X., Chen Y., Liao X., Liu D., Li F., Ruan H., Jia W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med. Oncol. 2013;30:588. doi: 10.1007/s12032-013-0588-6. PubMed DOI

Prensner J.R., Chen W., Iyer M.K., Cao Q., Ma T., Han S., Sahu A., Malik R., Wilder-Romans K., Navone N., et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014;74:1651–1660. doi: 10.1158/0008-5472.CAN-13-3159. PubMed DOI PMC

PCAT1 Gene-GeneCards|PCAT1 RNA Gene. [(accessed on 9 April 2018)]; Available online: http://www.genecards.org/cgi-bin/carddisp.pl?gene=PCAT1.

Zhai H., Sui M., Yu X., Qu Z., Hu J., Sun H., Zheng H., Zhou K., Jiang L. Overexpression of long non-coding RNA TUG1 promotes colon cancer progression. Med. Sci. Monit. 2016;22:3281–3287. doi: 10.12659/MSM.897072. PubMed DOI PMC

Sun J., Ding C., Yang Z., Liu T., Zhang X., Zhao C., Wang J. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J. Transl. Med. 2016;14:42. doi: 10.1186/s12967-016-0786-z. PubMed DOI PMC

Shen F., Cai W.S., Feng Z., Chen J., Feng J., Liu Q., Fang Y., Li K., Xiao H., Cao J., et al. Long non-coding RNA SPRY4-IT1 promotes colorectal cancer metastasis by regulate epithelial-mesenchymal transition. Oncotarget. 2017;8:14479–14486. doi: 10.18632/oncotarget.10407. PubMed DOI PMC

Yang Y., Shen Z., Yan Y., Wang B., Zhang J., Shen C., Li T., Ye C., Gao Z., Peng G., et al. Long non-coding RNA GAS5 inhibits cell proliferation, induces G0/G1 arrest and apoptosis, and functions as a prognostic marker in colorectal cancer. Oncol. Lett. 2017;13:3151–3158. doi: 10.3892/ol.2017.5841. PubMed DOI PMC

Ji Q., Zhang L., Liu X., Zhou L., Wang W., Han Z., Sui H., Tang Y., Wang Y., Liu N., et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br. J. Cancer. 2014;111:736–748. doi: 10.1038/bjc.2014.383. PubMed DOI PMC

Kwok Z.H., Roche V., Chew X.H., Fadieieva A., Tay Y. A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers. Int. J. Cancer. 2018;143:668–678. doi: 10.1002/ijc.31386. PubMed DOI

Kozera B., Rapacz M. Reference genes in real-time PCR. J. Appl. Genet. 2013;54:391–406. doi: 10.1007/s13353-013-0173-x. PubMed DOI PMC